Outlook Therapeutics (OTLK) said Wednesday preliminary results from the second of two clinical trials evaluating its experimental drug, ONS-5010, an opthalmic formulation of bevacizumab in wet age-related macular degeneration patients, did not meet the pre-specified non-inferiority endpoint in the special protocol assessment with the US Food and Drug Administration.
Shares of the company fell more than 82% in recent Wednesday premarket activity.
The company said its drug candidate, however, showed an improvement in vision and the presence of biologic activity, and a favorable safety profile.
It added that the final data analysis is expected by January 2025, and it plans to resubmit its Biologics License Application in Q1.
The drug developer is also preparing for a potential 2025 launch in the UK and Germany of Lytenav, the European brand of ONS-5010, where it has already been granted Marketing Authorization.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。